Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.
Clinical assessment of the response to antiangiogenic therapy has been cumbersome. A study in this issue of Cancer Cell demonstrates that a combination of magnetic resonance imaging (MRI) for quantification of normalized vessels with measurements of circulating levels of proangiogenic factors, including FGF2, SDF1, and viable circulating endothelial cells, provides an effective means to evaluate the response of recurrent glioblastoma to a prototypical pan-VEGF receptor tyrosine kinase inhibitor, AZD2171.
Hormigo
Adília
A
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Gutin
Philip H
PH
Rafii
Shahin
S
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011799:Quinazolines / Q000627:therapeutic use; D007211:Indoles
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011799:Quinazolines; C500926:cediranib; D007211:Indoles